Inactive Instrument

Company ATHENEXPAR

Equities

ATNX

US04685N2027

Business Summary

Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Number of employees: 275

Managers

Managers TitleAgeSince
Chief Executive Officer 63 03-10-31
Public Communications Contact - 16-12-31
Corporate Officer/Principal - 23-04-18
Corporate Officer/Principal - 18-06-30
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Human Resources Officer - 17-08-31
Corporate Officer/Principal 62 14-12-31
Comptroller/Controller/Auditor - 13-11-30

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 63 03-10-31
Director/Board Member 78 19-03-31
Director/Board Member 75 07-03-31
Director/Board Member 59 18-06-30
Director/Board Member 54 19-03-31
Director/Board Member 74 20-08-03
Director/Board Member 67 15-05-31
Director/Board Member 60 19-03-31

Company contact information

Athenex, Inc.

Conventus Building 1001 Main Street

14203-1009, Buffalo

+716 427 2950

http://www.athenex.com
address ATHENEXPAR(ATNX)

Sector

This company's sector is not yet available